Cullinan Therapeutics reports anti-leukemic activity in Phase 1 CLN-049 study
CGEM•Cullinan Therapeutics said a Phase 1 abstract reports anti-leukemic activity and a favorable safety profile for CLN-049 in relapsed or refractory leukemia or myelodysplastic syndrome. The company will present updated results for Phase 2-selected regimens at the ASH annual meeting on December 13.
1. ASH meeting presentations
Cullinan Therapeutics will present research on CLN-049 and velinotamig at the ASH annual meeting in New Orleans, December 12-15, 2026. Trial-in-progress posters will cover CLN-049 combination treatment for newly diagnosed acute myeloid leukemia and velinotamig for autoimmune cytopenias; preclinical findings will show velinotamig selectively targets BCMA-expressing B-lineage cells driving autoimmune cytopenias.
